Potentiators for cystic fibrosis – targeting the underlying molecular defect
- 1 June 2015
- journal article
- review article
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 16 (3) , 162-164
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Potentiators (specific therapies for class III and IV mutations) for cystic fibrosisCochrane Database of Systematic Reviews, 2015
- Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D MutationAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationChest, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Cystic Fibrosis Transmembrane Conductance Regulator Intracellular Processing, Trafficking, and Opportunities for Mutation-Specific TreatmentChest, 2011
- Cystic Fibrosis and Formes Frustes of CFTR-Related DiseaseRespiration, 2007
- The Phenotypic Consequences of CFTR MutationsAnnals of Human Genetics, 2003
- Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screeningHuman Mutation, 2002
- Delta F508 in cystic fibrosis: willing but not ableArchives of Disease in Childhood, 1997
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989